Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

482
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
482
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

940
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
940
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

361
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
361
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

552
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
552

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Gastrointestinal Complaints After Fundoplication: Rapid Review and Evidence Mapping.

Current gastroenterology reports·2026
Same author

Hyaluronic acid and chondroitin sulfate-based medical devices: formulations, esophageal mucosal protection, and their place in the management of GERD.

Therapeutic advances in gastroenterology·2025
Same author

Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates.

CPT: pharmacometrics & systems pharmacology·2024
Same author

Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.

Expert opinion on drug metabolism & toxicology·2024
Same author

Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge.

Therapeutic advances in gastroenterology·2024

相关实验视频

Updated: Jun 16, 2025

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.0K

竞争性酸阻塞剂:当前的临床使用和未来的发展

Carmelo Scarpignato1,2,3,4, Richard H Hunt5

  • 1Department of Medicine & Surgery, University of Parma, Parma, Italy. carmelo.scarpignato@unipr.it.

Current gastroenterology reports
|August 15, 2024
PubMed
概括

新的竞争性酸阻塞剂 (P-CABs) 改善了对诸如GERD和H. pylori感染等疾病的酸抑制,解决了传统质子抑制剂 (PPI) 的局限性. 对这些新型抗分泌药物需要进一步的长期安全数据.

关键词:
H. pylori 感染 感染 感染这就是Fexuprazan.格尔德 (GERD) 是一个很好的朋友.凯尔弗普拉赞 (Kerverprazan) 是一个名字.林纳普拉桑酸盐是什么 林纳普拉桑酸盐这就是P-CABs.个人隐私项目是个人隐私项目.这就是Tegoprazan.未满足的临床需求.这就是Vonoprazan.泽斯塔普拉赞 (Zestaprazan) 是一种药物.

更多相关视频

Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique
07:19

Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique

Published on: February 7, 2025

245
Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain
11:20

Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain

Published on: May 7, 2018

12.0K

相关实验视频

Last Updated: Jun 16, 2025

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.0K
Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique
07:19

Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique

Published on: February 7, 2025

245
Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain
11:20

Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain

Published on: May 7, 2018

12.0K

科学领域:

  • 胃肠病学 胃肠病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 质子抑制剂 (PPI) 是酸性相关疾病的标准,但有局限性.
  • 在管理GERD,H. pylori和NSAID相关的方面,仍然存在未满足的临床需求.
  • 限制包括不一致的酸性抑制和夜间酸度控制不良.

研究的目的:

  • 审查竞争性酸阻断剂 (P-CABs) 的现状和未来发展.
  • 突出P-CABs作为一种新的抗分泌药物类别.
  • 为了将P-CAB与现有的抑制酸的药物进行比较.

主要方法:

  • 对P-CAB和PPI的文献综述.
  • 对P-CABs在GERD和H. pylori根除中的临床试验数据的分析.
  • 疗效和安全性概况的比较.

主要成果:

  • P-CABs (vonoprazan,tegoprazan,fexuprazan,keverprazan) 解决了在酸性抑制方面尚未满足的需求.
  • 在GERD和H. pylori根除方面,P-CABs表现出与PPI相似或更高的疗效.
  • P-CABs的短期安全性与PPI相当;长期数据正在等待.

结论:

  • 在酸抑制治疗中,P-CABs代表了一个有前途的进步.
  • 这些新型药物为管理复杂的酸性疾病提供了潜在的解决方案.
  • 进一步的长期研究是必不可少的,以充分确定P-CABs的安全性.